Sanofi, Opella

Sanofi in Exclusive Talks With CD&R Over Sale of $17 Billion Opella
PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).
Sanofi Enters Exclusive Talks With CD&R Over Consumer Business Stake Sale
Sanofi entered into exclusive talks to sell a controlling stake in its consumer-healthcare business Opella to Clayton Dubilier & Rice in a deal that values the business as a whole at 16 billion euros ($17.
Sanofi Enters Exclusive Negotiations To Sell 50% Stake In Opella To CD&R
Sanofi (SNYNF) announced it has entered into exclusive negotiations to sell a 50 percent controlling stake in its consumer healthcare
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale
Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in its consumer healthcare (CHC) business unit,
Sanofi and CD&R enter exclusive talks for Opella sale
Sanofi (EPA:SASY)(NASDAQ:SNY) has entered into exclusive negotiations with private equity firm Clayton, Dubilier & Rice to sell a controlling stake in its consumer healthcare unit, Opella. This move marks a shift for Sanofi,
Sanofi Enters Exclusive Talks to Sell 50% Stake in Opella to CD&R
Sanofis Exclusive Negotiations with Clayton Dubilier Rice Sanofi (NASDAQ: SNY) announced on Monday that it has entered exclusive negotiations to sell a 50% controlling stake in its consumer health division,
BioPharma Dive11h
Dengue is spreading and Sanofi is pulling the US market’s only vaccine. What’s next?
As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...
Sanofi Deal Jitters Imperil Stock’s Big Rebound
The French drugmaker on Monday announced progress on a deal to sell 50% of its over-the-counter division to Clayton Dubilier ...
The Global Legal Post3h
Kirkland, Freshfields, Bredin Prat called in for €16bn sale of Sanofi’s consumer health arm
Sale to US private equity firm Clayton Dubilier & Rice comes as investors anticipate more and larger European PE buyouts ...
Sanofi announces presentation of Dupixent Phase 3 data in CSU
Data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent in biologic-naive patients with uncontrolled chronic ...
Sanofi Expected to Report Higher Sales; Capital Allocation in Focus -- Earnings Preview
SALES FORECAST: The Paris-based group's sales are forecast at 12.63 billion euros, according to Visible Alpha. That compares with 11.96 billion euros for the same period the year before. As of ...
Sanofi Pursues Sale Of Painkiller After Political Controversy
Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, ...
CD&R Faces Tough Road to 20% Returns With Sanofi
The US buyout firm is pairing with the French pharma giant to buy out its consumer unit. Success here requires much more than ...
2minutemedicine.com2d
Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients
Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...
Regeneron, Sanofi announce presentation of Dupixent Phase 3 data in CSU
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will present data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use ...
Sanofi Set to Sign Consumer Health Deal With CD&R This Weekend
Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice ...